The goal of this clinical trial is to determine the effects of estrogen (Fenmotong) and Qingxin Zishen Decoction on the levels of kisspeptin, NKB, and dynorphin expressed in human KNDy neurons Between patients with menopausal syndrome. The aims of the study are as follows:

• Find a new neuroendocrine mechanism of Qingxin Zishen Decoction in the treatment of menopausal syndrome.
• Evaluate the changes of new neuroendocrine indicators in the clinical treatment of menopausal syndrome.
• Develop non-hormonal drugs with definite efficacy in the treatment of menopausal syndrome.

Participants will randomly divided into the experimental group and the control group, the experimental group will be oral fenmotong, and the control group will be oral Qingxin Zi Kidney Decoction, and the efficacy, sex hormone levels and neuroendocrine index changes of the two groups will be compared.

Inclusion Criteria:

• Women aged 41~55;
• KIM score≥ 15 points;
• The number of hot flashes and sweating≥ 3 times/day;
• Menopause time≥ 6 months;
• FSH>30mIU/ml,E2<30ng/L;
• Informed consent, voluntary testing.

Exclusion Criteria:

• Unexplained vaginal bleeding;
• Sex hormone-related malignant tumors cannot be excluded;
• premature ovarian failure, or endometriosis, or hysterectomy, or bilateral adnexectomy;
• Combined with primary liver and kidney dysfunction, cardiovascular and cerebrovascular diseases, blood system diseases and other serious diseases that affect their survival;
• Exposure to sex hormone-related drugs within 3 months;
• Patients with mental abnormalities, or those with a history of alcohol or drug abuse;
• Those who have allergic reactions to the study drug;
• Those who are participating in other drug clinical researchers.